NCT07080775View on ClinicalTrials.gov

The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 5, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

August 30, 2029

Conditions
Parkinson's Disease
Interventions
DRUG

human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection

5.0×10\^7 cells/mL, injection, once, 12 months

Trial Locations (1)

100070

RECRUITING

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Tiantan Hospital

OTHER

lead

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

INDUSTRY